The Novel TFEB Agonist Desloratadine Ameliorates Hepatic Steatosis by Activating the Autophagy-lysosome Pathway

Overview

Journal Front Pharmacol

Date 2024 Oct 3

PMID 39359254

Authors

Jieru Lin

Chunhuan Huang

Jingye Zhao

Lu Li

Zhenwei Wu

Tingyu Zhang

Yuyin Li

Wei Li

Baoqiang Guo

Zhenxing Liu

Aipo Diao

Affiliations

Soon will be listed here.

Abstract

The autophagy-lysosome pathway plays an essential role in promoting lipid catabolism and preventing hepatic steatosis in non-alcoholic fatty liver disease (NAFLD). Transcription factor EB (TFEB) enhances the autophagy-lysosome pathway by regulating the expression of genes related to autophagy and lysosome biogenesis. Therefore, targeting TFEB provides a novel strategy for the treatment of lipid metabolic diseases. In this study, the antiallergic drug desloratadine was screened and identified as a novel TFEB agonist. Desloratadine effectively induced translocation of TFEB to the nucleus and promoted autophagy and lysosome biogenesis. Desloratadine-induced TFEB activation was dependent on AMPK rather than mTORC1. Moreover, desloratadine treatment enhanced clearance of lipid droplets in cells induced by fatty acids oleate and palmitate. Furthermore, high-fat diet (HFD) induced obesity mouse model experiments indicated treatment with desloratadine markedly reduced the body weight of HFD-fed mice, as well as the levels of hepatic triglycerides and total cholesterol, serum glutamic pyruvic transaminase and glutamic-oxaloacetic transaminase. Oil red O staining showed the liver fat was significantly reduced after desloratadine treatment, and H&E staining analysis demonstrated hepatocellular ballooning was improved. In addition, autophagy and lysosomal biogenesis was stimulated in the liver of desloratadine treated mice. Altogether, these findings demonstrate desloratadine ameliorates hepatic steatosis through activating the TFEB-mediated autophagy-lysosome pathway, thus desloratadine has an exciting potential to be used to treat fatty liver disease.

References

Vidicevic-Novakovic S, Stanojevic Z, Tomonjic N, Karapandza K, Zekovic J, Martinovic T . Proapoptotic and proautophagy effect of H1-receptor antagonist desloratadine in human glioblastoma cell lines. Med Oncol. 2023; 40(8):241. DOI: 10.1007/s12032-023-02117-3. View

Wang C, Niederstrasser H, Douglas P, Lin R, Jaramillo J, Li Y . Small-molecule TFEB pathway agonists that ameliorate metabolic syndrome in mice and extend C. elegans lifespan. Nat Commun. 2017; 8(1):2270. PMC: 5741634. DOI: 10.1038/s41467-017-02332-3. View

Gupta S, Banfield C, Affrime M, Marco A, Cayen M, Herron J . Desloratadine demonstrates dose proportionality in healthy adults after single doses. Clin Pharmacokinet. 2002; 41 Suppl 1:1-6. DOI: 10.2165/00003088-200241001-00001. View

Martina J, Chen Y, Gucek M, Puertollano R . MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB. Autophagy. 2012; 8(6):903-14. PMC: 3427256. DOI: 10.4161/auto.19653. View

Singh R, Kaushik S, Wang Y, Xiang Y, Novak I, Komatsu M . Autophagy regulates lipid metabolism. Nature. 2009; 458(7242):1131-5. PMC: 2676208. DOI: 10.1038/nature07976. View

Zechner R, Madeo F, Kratky D . Cytosolic lipolysis and lipophagy: two sides of the same coin. Nat Rev Mol Cell Biol. 2017; 18(11):671-684. DOI: 10.1038/nrm.2017.76. View

Anstee Q, Targher G, Day C . Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013; 10(6):330-44. DOI: 10.1038/nrgastro.2013.41. View

Sodum N, Kumar G, Bojja S, Kumar N, Rao C . Epigenetics in NAFLD/NASH: Targets and therapy. Pharmacol Res. 2021; 167:105484. DOI: 10.1016/j.phrs.2021.105484. View

Malik N, Ferreira B, Hollstein P, Curtis S, Trefts E, Novak S . Induction of lysosomal and mitochondrial biogenesis by AMPK phosphorylation of FNIP1. Science. 2023; 380(6642):eabj5559. PMC: 10794112. DOI: 10.1126/science.abj5559. View

10.

Grabner G, Xie H, Schweiger M, Zechner R . Lipolysis: cellular mechanisms for lipid mobilization from fat stores. Nat Metab. 2021; 3(11):1445-1465. DOI: 10.1038/s42255-021-00493-6. View

11.

Du X, Di Malta C, Fang Z, Shen T, Niu X, Chen M . Nuciferine protects against high-fat diet-induced hepatic steatosis and insulin resistance activating TFEB-mediated autophagy-lysosomal pathway. Acta Pharm Sin B. 2022; 12(6):2869-2886. PMC: 9214335. DOI: 10.1016/j.apsb.2021.12.012. View

12.

Qian H, Chao X, Williams J, Fulte S, Li T, Yang L . Autophagy in liver diseases: A review. Mol Aspects Med. 2021; 82:100973. PMC: 9585624. DOI: 10.1016/j.mam.2021.100973. View

13.

Paquette M, El-Houjeiri L, Zirden L, Puustinen P, Blanchette P, Jeong H . AMPK-dependent phosphorylation is required for transcriptional activation of TFEB and TFE3. Autophagy. 2021; 17(12):3957-3975. PMC: 8726606. DOI: 10.1080/15548627.2021.1898748. View

14.

Sardiello M, Palmieri M, di Ronza A, Medina D, Valenza M, Gennarino V . A gene network regulating lysosomal biogenesis and function. Science. 2009; 325(5939):473-7. DOI: 10.1126/science.1174447. View

15.

Roczniak-Ferguson A, Petit C, Froehlich F, Qian S, Ky J, Angarola B . The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosome homeostasis. Sci Signal. 2012; 5(228):ra42. PMC: 3437338. DOI: 10.1126/scisignal.2002790. View

16.

Martinez-Lopez N, Singh R . Autophagy and Lipid Droplets in the Liver. Annu Rev Nutr. 2015; 35:215-37. PMC: 7909712. DOI: 10.1146/annurev-nutr-071813-105336. View

17.

Li W, He P, Huang Y, Li Y, Lu J, Li M . Selective autophagy of intracellular organelles: recent research advances. Theranostics. 2021; 11(1):222-256. PMC: 7681076. DOI: 10.7150/thno.49860. View

18.

Murdoch D, Goa K, Keam S . Desloratadine: an update of its efficacy in the management of allergic disorders. Drugs. 2003; 63(19):2051-77. DOI: 10.2165/00003495-200363190-00010. View

19.

Loomba R, Friedman S, Shulman G . Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021; 184(10):2537-2564. DOI: 10.1016/j.cell.2021.04.015. View

20.

Napolitano G, Ballabio A . TFEB at a glance. J Cell Sci. 2016; 129(13):2475-81. PMC: 4958300. DOI: 10.1242/jcs.146365. View